Viewing nowCombinationDucafin Tablets 60/5 mg
Fimasartan Potassium Trihydrate 66.01mg · S-Amlodipine Besylate 2.5 Hydrate 7.48mg
Tablet · Prescription medication · Combination
Aprogen Biologics Co., Ltd.

MFDS item code 202300098 · Approved 2023.01.06
Treatment of essential hypertension inadequately controlled with fimasartan monotherapy
This medication is used in patients with essential hypertension when blood pressure is not sufficiently controlled by monotherapy with Pimasartan Potassium.
The recommended dose of this medicine is 1 tablet once daily, taken with water, with or without food. If possible, it is recommended to take it at the same time each day (e.g., in the morning). It is recommended that the dose be adjusted with fimasartan before administering this medicine. However, if blood pressure is not controlled as described below, switching directly to this medicine may be considered. ㆍ 30/2.5 milligrams: For patients whose blood pressure is not adequately controlled with fimasartan 30 milligrams alone. ㆍ 60/2.5 milligrams: For patients whose blood pressure is not adequately controlled with fimasartan 60 milligrams alone. ㆍ 60/5 milligrams: For patients whose blood pressure is not adequately controlled with fimasartan 60 milligrams alone or this medicine 60/2.5 milligrams. Patients taking fimasartan and S-amlodipine (amlodipine) concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. Elderly patients No initial dose adjustment is required for elderly patients aged 70 years or younger. Patients with renal impairment No dose adjustment is required in patients with mild to moderate renal impairment (creatinine clearance 30 ~ 80 mL/min). For patients with severe renal impairment (creatinine clearance < 30 mL/min), treatment should be initiated with fimasartan 30 milligrams in this medicine. Patients with hepatic impairment No dose adjustment is required in patients with mild hepatic impairment. This medicine should not be administered to patients with moderate to severe hepatic impairment.
The safety and efficacy of this medicine have not been established in children and adolescents aged 18 years or younger.
This medication can cause serious harm or death to the fetus and newborn if taken during pregnancy, especially in the 2nd and 3rd trimesters, so it should be discontinued immediately upon confirmation of pregnancy. Patients with hypersensitivity to any of the components, women who are pregnant or breastfeeding, patients undergoing renal dialysis, patients with moderate to severe liver dysfunction, biliary obstruction, diabetic patients with certain renal impairments, certain genetically lactose-intolerant patients, patients with severe aortic stenosis, and patients in shock should not be administered this medication. Extra care should be taken when administering this medication to patients with reduced blood volume or sodium levels, impaired kidney function, renal artery hypertension, aortic and mitral stenosis, primary hyperaldosteronism, severe hypotension, elderly patients, and patients allergic to specific pigment components. Side effects may include dizziness, headache, facial swelling, urination disorders, insomnia, flushing, and in rare cases, severe renal impairment, blood pressure drop, and allergic reactions have been reported. Hypotension or electrolyte imbalances may occur during treatment, especially in patients on high-dose diuretics, who should be closely monitored for signs of hypotension. Patients with heart failure or impaired kidney function should have their potassium levels regularly checked through blood tests due to the risk of elevated serum potassium. In patients with renal artery stenosis, there may be an increased risk of worsening kidney function and hypotension, so administration should be done cautiously. This medication may increase blood pressure-lowering effects or worsen side effects when used in combination with other antihypertensives, so it should be administered according to healthcare professionals' instructions during combined therapy. Due to potential risks to the fetus, women taking this medication should consult with healthcare professionals if planning to become pregnant or if pregnant. Breastfeeding women are advised to either discontinue breastfeeding or the medication, as it may be excreted in breast milk. Safety and efficacy in pediatric patients under 18 years have not been established, thus it is not recommended for this age group. Elderly patients may be more sensitive to this medication, so any changes in symptoms should be closely monitored upon administration. This medication should not be administered to patients with moderate to severe liver dysfunction. In cases of overdose, severe blood pressure drop, heart irregularities, shock, and other symptoms may occur, requiring immediate assistance from healthcare professionals and emergency care if necessary. This medication should be kept out of reach of children, and transferring it to another container is not advisable for quality maintenance and safety.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a specially designed container that prevents light and air penetration, and should be kept at a temperature between 1 to 30 degrees Celsius at room temperature. This storage method safely maintains the effectiveness of the medication.
Orange rounded square film-coated tablet
30 tablets/bottle, 300 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationFimasartan Potassium Trihydrate 66.01mg · S-Amlodipine Besylate 2.5 Hydrate 7.48mg
Tablet · Prescription medication · Combination
Aprogen Biologics Co., Ltd.
CombinationFimasartan Potassium Trihydrate 66.01mg · S-Amlodipine Besylate 2.5 Hydrate 7.48mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 66.01mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
NBK Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Ajou Pharmaceuticals Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Kips Biopharma Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Bionex Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.